Leitlinie „Behandlung der Akne“ - AWMF

013/017 - Behandlung der Akne aktueller Stand: 02/2010
korrigierte Fassung: 10/2011
131. Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U.
Coping with acne vulgaris. Evaluation of the chronic skin disorder questionnaire in
patients with acne. Dermatology. 1998; 196: 108-15.
132. Thiboutot D, Dreno B, Layton A. Acne counseling to improve adherence. Cutis. 2008;
81: 81-6.
133. Davies E, Patel C, Salek MS, Finlay AY. Does ad hoc quality-of-life discussion in
inflammatory skin disease consultations reflect standardized patient-reported
outcomes? Clin Exp Dermatol. 2008; 33: 16-21.
134. Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and
quality of life in mild to moderate acne. Dermatology. 2008; 217: 309-14.
135. Pawin H, Beylot C, Chivot M, Faure M, Poli F, Revuz J, Dreno B. Creation of a tool
to assess adherence to treatments for acne. Dermatology. 2009; 218: 26-32.
136. Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am
Acad Dermatol. 1995; 32: S42-8.
137. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria
clinically relevant? : implications of resistance for acne patients and prescribers. Am J
Clin Dermatol. 2003; 4: 813-31.
138. Fluhr JW, Gloor M, Dietz P, Hoffler U. In Vitro activity of 6 antimicrobials against
propionibacteria isolates from untreated acne papulopustulosa. Zentralbl Bakteriol.
1999; 289: 53-61.
139. Ross JI, Eady EA, Cove JH, Ratyal AH, Cunliffe WJ. Resistance to erythromycin and
clindamycin in cutaneous propionibacteria is associated with mutations in 23S rRNA.
Dermatology. 1998; 196: 69-70.
140. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G,
Katsambas A, Galvan Perez Del Pulgar JI, Rollman O, Torok L, Eady EA, Cove JH.
Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003; 148: 467-78.
141. Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne
study. Arch Dermatol. 1981; 117: 551-3.
142. Perez Lopez M, Moragas Vinas JM. Nueva sal de eritromicina (A-137 o laurilsulfato
de eritromicina) en el tratamiento topico del acne. Med Cutan Ibero Lat Am. 1982; 10:
151-8.
143. Prince RA, Busch DA, Hepler CD, Feldick HG. Clinical trial of topical erythromycin
in inflammatory acne. Drug Intell Clin Pharm. 1981; 15: 372-6.
144. Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapy in
moderately severe acne. Arch Dermatol. 1975; 111: 997-1000.
145. Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF. Comparison of
the efficacy and safety of a combination topical gel formulation of benzoyl peroxide
and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments
of acne vulgaris. Am J Clin Dermatol. 2001; 2: 33-9.
146. Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and
bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group
comparison study versus cream base. J Am Acad Dermatol. 1991; 25: 674-81.
Seite 114 von 136